이터나 테라퓨틱스(ERNA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.83 (+1.86%), 시가총액 $0.01B, 52주 최저~최고 $0.15 ~ $7.82.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusett
이터나 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이터나 테라퓨틱스의 현재 주가는 $3.83 (+1.86%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이터나 테라퓨틱스의 시가총액은 약 $0.01B입니다.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's l